Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription 13.07.2026 1 Am J Ind Med 4 Ann Surg Oncol 4 BMC Cancer 7 Cancer Lett 1 Cancer Res 1 Carcinogenesis 2 Chest 1 Clin Cancer Res 6 Clin Nucl Med 2 Eur J Cancer 1 Int J Cancer 1 Int J Oncol 1 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 2 J Clin Oncol 1 J Natl Cancer Inst 2 J Thorac Oncol 1 JAMA Oncol 3 Lung Cancer 1 N Engl J Med 1 Oncogene 2 PLoS One 1 Science

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Ind Med

1. GRANADOS G, Cruz MJ, Urrutia-Landa I, Bronte-Moreno O, et al
   Asbestos-Related Respiratory Diseases in Spain: Insights From the Spanish Registry.
   Am J Ind Med. 2026;69:614-621.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. BAKALOV V, Shersher DD
   The Dual Face of PD-L1 in Perioperative EGFR-Mutated Lung Cancer-Promise, Paradox, and the Path Forward.
   Ann Surg Oncol. 2026 Jul 8. doi: 10.1245/s10434-026-20064.
   PubMed        
   
   
3. KANZAKI R, Okami J
   ASO Author Reflections: Reconsidering Surgical Indications for Clinical T4 Non-Small Cell Lung Cancer in the TNM 9th Edition Era.
   Ann Surg Oncol. 2026 Jul 6. doi: 10.1245/s10434-026-20056.
   PubMed        
   
   
4. GENG J, Guan T, Zeng X, Cui Z, et al
   Artificial Intelligence-Driven Three-Dimensional Reconstruction System Reduced Unexpected Procedural Changes in Thoracic Surgery.
   Ann Surg Oncol. 2026;33:7151-7161.
   PubMed         Abstract available
   
   
5. FACCIOLI RM, Heise LM, Lauricella LL, Pego-Fernandes PM, et al
   PneumoScore: Risk Prediction Model for 90-Day Mortality After Lung Resection.
   Ann Surg Oncol. 2026;33:7123-7132.
   PubMed         Abstract available
   
   

   
   BMC Cancer

6. HASNAIN AN, Telange DR, Kapoor DU
   Hyaluronic acid- bovine serum albumin coated nanostructured lipid carriers for targeted combinational delivery of fisetin and flavokawain A in non-small cell lung cancer.
   BMC Cancer. 2026 Jul 10. doi: 10.1186/s12885-026-16484.
   PubMed         Abstract available
   
   
7. ZHOU Y, Lau B, Rudolph JE, Xu X, et al
   Sex- and age- specific lung cancer incidence and mortality among Medicaid beneficiaries with and without HIV, 2001-2015.
   BMC Cancer. 2026 Jul 7. doi: 10.1186/s12885-026-16487.
   PubMed         Abstract available
   
   
8. VAN DINH L, Nguyen NBT, Vu TQ, Dang HH, et al
   Real-world efficacy of first- and second-generation EGFR TKIs in NSCLC with EGFR co-mutations: a Vietnamese cohort study.
   BMC Cancer. 2026;26:822.
   PubMed         Abstract available
   
   
9. ZHANG S, Liu J, Feng X, Feng R, et al
   Osimertinib-induced interstitial lung disease insights from faers signal detection and network toxicology analysis.
   BMC Cancer. 2026;26:824.
   PubMed         Abstract available
   
   

   
   Cancer Lett

10. WANG L, Liu Y, Zhao W, Xing L, et al
    Chinese Expert Consensus on Radiotherapy Combined with Immunotherapy for Unresectable Lung Cancer (2026 Edition).
    Cancer Lett. 2026 Jul 7:218719. doi: 10.1016/j.canlet.2026.218719.
    PubMed         Abstract available
    
    
11. MUNEER A, Showkatian E, Saad MB, Hong L, et al
    Deep learning of CT imaging predicts PD-L1 expression and immunotherapy response in metastatic NSCLC: A multi-center study.
    Cancer Lett. 2026;656:218687.
    PubMed         Abstract available
    
    
12. ALEMAN JD, Young CD, Ke Y, Nguyen KA, et al
    Ectopic integrin beta1 overproduction by squamous carcinoma cells contributes to immune evasion-associated metastasis.
    Cancer Lett. 2026;656:218635.
    PubMed         Abstract available
    
    
13. YE T, Chen M, Hu Y, Yang Z, et al
    Vesicular QSOX1-MMP2 from inflammatory cancer-associated fibroblasts degrades the extracellular matrix to drive colorectal cancer pulmonary dissemination.
    Cancer Lett. 2026 May 29:218645. doi: 10.1016/j.canlet.2026.218645.
    PubMed         Abstract available
    
    
14. PULIDO I, Garcia-Canaveras JC, Rodriguez ML, Becker JH, et al
    NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC.
    Cancer Lett. 2025;633:218032.
    PubMed         Abstract available
    
    
15. ZHAO J, Shen M, Xu X, Ji S, et al
    Proteomics and single cell profiling identify keratin driven preexisting immunity influences lung squamous carcinoma neoadjuvant therapy.
    Cancer Lett. 2025;633:218000.
    PubMed         Abstract available
    
    
16. ZHOU D, Zhang J, Deng X, Lu X, et al
    SUSD2 hypersialylation promotes early lung adenocarcinoma progression by driving ECM remodeling and pro-tumorigenic fibroblast activation.
    Cancer Lett. 2025;633:217995.
    PubMed         Abstract available
    
    

    
    Cancer Res

17. SEN T, Gobbini E, Mustafayev K, Spiegelman LS, et al
    Neurotropism and Therapeutic Targeting of Brain Metastases in Small Cell Lung Cancer.
    Cancer Res. 2026 Jul 9. doi: 10.1158/0008-5472.CAN-25-5968.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

18. AGGISON J, Medina C, Wu S, Li N, et al
    Asbestos exposure induces malignant-like phenotypes via minority MOMP and displays characteristics of drug-tolerant persister cells.
    Carcinogenesis. 2026;47:bgag030.
    PubMed         Abstract available
    
    

    
    Chest

19. BENJAMIN LN, Nunez ER, Chen L, Motwani Y, et al
    Lung Cancer Screening Centralization Is Associated With Improved Screening Uptake: The Veterans Healthcare Administration's Experience 2015-2021.
    Chest. 2026 Jul 8:S0012-3692(26)00949-9. doi: 10.1016/j.chest.2026.
    PubMed         Abstract available
    
    
20. OSTROFF JS, Shelley D, Chichester LR, Schofield E, et al
    An Optimization Randomized Clinical Trial to Identify an Effective, Efficient Smoking Cessation Intervention in the Context of Lung Cancer Screening: Cessation and Screening to Save Lives (CASTL).
    Chest. 2026 Jul 8:S0012-3692(26)00944-X. doi: 10.1016/j.chest.2026.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

21. HUANG J, Aldea M, Miller KW, Rotow JK, et al
    Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.
    Clin Cancer Res. 2026 Jul 6. doi: 10.1158/1078-0432.CCR-26-0188.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

22. SHIMOTSU R, Karube Y, Nakadate M, Kubota K, et al
    Chest Wall Hibernoma With Intense 18F-FDG Uptake on PET/CT Mimicking Malignant Pleural Mesothelioma.
    Clin Nucl Med. 2026 Apr 16. doi: 10.1097/RLU.0000000000006492.
    PubMed         Abstract available
    
    
23. ZHANG J, Dong A, Wang Y
    Intense FDG Uptake of Lung Metastases From Succinate Dehydrogenase-deficient Renal Cell Carcinoma.
    Clin Nucl Med. 2026;51:677-679.
    PubMed         Abstract available
    
    
24. HUANG JJ, Zhu HY, Cheng Y, Shao D, et al
    PET/CT Features of Granulomatosis With Polyangiitis Mimicking Left Lung and Tracheal Malignancy.
    Clin Nucl Med. 2026 Feb 24. doi: 10.1097/RLU.0000000000006304.
    PubMed         Abstract available
    
    
25. TIAN C, Xie LB, Liu Z, Chen Y, et al
    Remarkable Response to 177 Lu-PSMA and 177 Lu-DOTA-IBA Cocktail Therapy in a Patient With Dual Primary Malignancies.
    Clin Nucl Med. 2026;51:664-666.
    PubMed         Abstract available
    
    
26. DU T, Lin P, Liu C, Liu B, et al
    Elevated FAPI Activity in Lung Metastases in a Pediatric Thyroid Cancer Patient With Thyroglobulin Elevation and Negative Iodine Scintigraphy.
    Clin Nucl Med. 2026 Feb 2. doi: 10.1097/RLU.0000000000006351.
    PubMed         Abstract available
    
    
27. GUPTA N, Bora RR, Aiyer HM, Agarwal P, et al
    Pulmonary Eosinophilia Mimicking Metastatic Lung Lesions on FDG PET-CT: A Diagnostic Pitfall.
    Clin Nucl Med. 2026 Jan 19. doi: 10.1097/RLU.0000000000006339.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

28. ANDERSEN R, Jespersen MS, Presti M, Bjornhart B, et al
    Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.
    Eur J Cancer. 2026;243:116872.
    PubMed         Abstract available
    
    
29. TAGLIAMENTO M, Bruzzone M, Blondeaux E, Dall'Olio F, et al
    Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.
    Eur J Cancer. 2026;243:116867.
    PubMed         Abstract available
    
    

    
    Int J Cancer

30. SUN Y, Liu X, Zhu Q, Sun Z, et al
    The Efficacy and Safety of AI With Anlotinib Versus AI for Treating Synovial Sarcoma Patients With Lung Metastasis: A Retrospective Cohort Study.
    Int J Cancer. 2026;159:1274-1281.
    PubMed         Abstract available
    
    

    
    Int J Oncol

31. ZHU J, Chen M, Chen N, Ma A, et al
    [Retracted] Glycyrrhetinic acid induces G1?phase cell cycle arrest in human non?small cell lung cancer cells through endoplasmic reticulum stress pathway.
    Int J Oncol. 2026;69:97.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

32. HOEKSTRA N, Kim DH, Vicini FA, Park S, et al
    The impact of breast radiation technique on secondary lung cancer risk modeling: An analysis based on clinically delivered lung doses of various modern radiation techniques and target volumes.
    Int J Radiat Oncol Biol Phys. 2026 Jul 8:S0360-3016(26)03943.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

33. CHEN Q, Mo S, Cheng J, Zhu L, et al
    Single-cell hdWGCNA identifies checkpoint inhibitor pneumonitis-linked CD4 + T-cell subsets driving immunotherapy response and prognosis in lung cancer.
    J Cancer Res Clin Oncol. 2026 Jul 10. doi: 10.1007/s00432-026-06522.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

34. LI Y, Faroni L, Ynoe Moraes F
    Brain-Only Progression After First-Line Therapy in Extensive-Stage Small Cell Lung Cancer: Treat the Sanctuary, Preserve the Backbone.
    J Clin Oncol. 2026 Jul 7:JCO2601076. doi: 10.1200/JCO-26-01076.
    PubMed        
    
    
35. DOROSHOW DB, Leal TA, Waqar SN, Borghaei H, et al
    Erratum: Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.
    J Clin Oncol. 2026 Jul 8:JCO2601603. doi: 10.1200/JCO-26-01603.
    PubMed        
    
    

    
    J Natl Cancer Inst

36. BRAY F
    Stat Bite: Time trends in lung cancer mortality in four European countries by sex, all ages combined, 1951-2022.
    J Natl Cancer Inst. 2026;118:1337.
    PubMed        
    
    

    
    J Thorac Oncol

37. CANI M, Bafunno D, Caumo F, Novello S, et al
    Cytisine for Smoking Cessation Within a Lung Cancer Screening Program: Results From the Italian RISP Trial.
    J Thorac Oncol. 2026 Jul 6:104071. doi: 10.1016/j.jtho.2026.104071.
    PubMed         Abstract available
    
    
38. LEE JY, Kim S, Na KJ, Goo JM, et al
    Germline Mutations as Risk Factors for Lung Cancer: A Systematic Review and Meta-analysis.
    J Thorac Oncol. 2026 Jul 6:104069. doi: 10.1016/j.jtho.2026.104069.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

39. BOZORGMEHR F, Chung I, Behnisch R, Weykamp F, et al
    Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320).
    JAMA Oncol. 2026 Jul 9. doi: 10.1001/jamaoncol.2026.2330.
    PubMed         Abstract available
    
    

    
    Lung Cancer

40. MORITA A, Rai K, Kuribayashi T, Tomida S, et al
    ULK1, a novel therapeutic target to delay drug tolerance to EGFR-TKIs in an EGFR-mutant non-small cell lung cancer model.
    Lung Cancer. 2026;218:109516.
    PubMed         Abstract available
    
    
41. KUMAR RR, Enoch IV
    Nanoparticle-based drug delivery for precision lung cancer therapy: Tumor microenvironment modulation and theranostic applications.
    Lung Cancer. 2026;219:109518.
    PubMed         Abstract available
    
    
42. ISAKA T, Kenmotsu H, Wakabayashi M, Yoshioka H, et al
    Adjuvant chemotherapy intensity and prognosis in completely resected high-grade neuroendocrine lung carcinoma: a post hoc analysis of JCOG1205/1206.
    Lung Cancer. 2026;219:109520.
    PubMed         Abstract available
    
    

    
    N Engl J Med

43. YUE D, Huang M, Song P, Chen Y, et al
    Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2026;395:151-161.
    PubMed         Abstract available
    
    

    
    Oncogene

44. MENG Y, Wang X, Wu S, Lin W, et al
    USP20-mediated PGAM1 stabilization promotes glycolysis and confers osimertinib resistance in non-small cell lung carcinoma.
    Oncogene. 2026 Jul 8. doi: 10.1038/s41388-026-03889.
    PubMed         Abstract available
    
    

    
    PLoS One

45. CHEN H, Fan B, Yuan M, Wang D, et al
    Predicting T790M mutation status in non-small cell lung cancer based on radiomics: A systematic review and meta-analysis.
    PLoS One. 2026;21:e0353257.
    PubMed         Abstract available
    
    
46. ZHANG K, Zhou X, Zhang Y, Jin G, et al
    Diagnostic performance of machine learning models based on dual-phase 99mTc-MIBI SPECT/CT semiquantitative parameters for differentiating benign and malignant pulmonary nodules.
    PLoS One. 2026;21:e0353271.
    PubMed         Abstract available
    
    

    
    Science

47. GULTEKIN Y, Vander Heiden MG
    Local signals, systemic decline.
    Science. 2026;393:33-34.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum